You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The groups will use Helomics' artificial intelligence-based platform to develop tools to provide predictive therapeutic recommendations for ovarian and thyroid cancers.
Clinical trials investigating whether epigenetic treatment can restore susceptibility to other treatments are underway in colorectal, lung, and breast cancers.
The MammaSeq assay comprises 79 genes and 1,369 mutations in breast cancer that could be used as potential downstream therapeutic targets.
Through prospective pancreatic ductal adenocarcinoma testing, researchers saw germline mutations in new genes and in cases outside of current germline testing criteria.